Evotec AG Announces the Acquisition of all Shares of Neuro3d
3/29/2007 11:48:44 AM
More...
|
Neuro3d Reports Positive Results From Phase II Trials Of Ocaperidone In Schizophrenia
10/19/2005 5:13:15 PM
More...
|
Neuro3d Initiates Phase I Trials With ND7001, A New Mechanism Antidepressant And Anxiolytic Compound
10/19/2005 5:12:32 PM
More...
|
Neuro3d's Third Round: EUR31.5M For Development Of Lead Drugs
10/19/2005 5:11:51 PM
More...
|
BioPartnering Europe 2004 Exhibitor Profiles
10/19/2005 5:11:47 PM
More...
|
Neuro3d Commences Clinical Studies With Its PDE4 Inhibitor ND1251 A New Approach For Treating Patients With Depression
10/19/2005 5:11:34 PM
More...
|
Neuro3d Completes A EUR 31.5 Million Third Round Financing
10/19/2005 5:10:53 PM
More...
|
Neuro3d Receives Support From ANVAR For Ongoing Clinical Development Of Its Antidepressant ND1251
10/19/2005 5:08:59 PM
More...
|
Neuro3d Identifies Candidate Compound And Extends Collaboration
10/19/2005 5:08:50 PM
More...
|